Association Between Pediatric Clinical Trials and Global Burden of Disease

Abstract

BACKGROUND: The allocation of research resources should favor conditions responsible for the greatest disease burden. This is particularly important in pediatric populations, which have been underrepresented in clinical research. Our aim was to measure the association between the focus of pediatric clinical trials and burden of disease and to identify neglected clinical domains. METHODS: We performed a cross-sectional study of clinical trials by using trial records in ClinicalTrials.gov. All trials started in 2006 or after and studying patient-level interventions in pediatric populations were included. Age-specific measures of disease burden were obtained for 21 separate conditions for high-, middle-, and low-income countries. We measured the correlation between number of pediatric clinical trials and disease burden for each condition. RESULTS: Neuropsychiatric conditions and infectious diseases were the most studied conditions globally in terms of number of trials (874 and 847 trials, respectively), while intentional injuries (5 trials) and maternal conditions (4 trials) were the least studied. Clinical trials were only moderately correlated with global disease burden (r = 0.58, P = .006). Correlations were also moderate within each of the country income levels, but lowest in low-income countries (r = .47, P = .03). Globally, the conditions most understudied relative to disease burden were injuries (–260 trials for unintentional injuries and –160 trials for intentional injuries), nutritional deficiencies (–175 trials), and respiratory infections (–171 trials). CONCLUSIONS: Pediatric clinical trial activity is only moderately associated with pediatric burden of disease, and least associated in low-income countries. The mismatch between clinical trials and disease burden identifies key clinical areas for focus and investment.

A child abuse research network: Now what?

“…[cite Maholmes commentary] While child maltreatment is likely to remain under-funded relative to its impact on pediatric morbidity and mortality, (Bourgeois, Olson, Ioannidis, & Mandl, 2013) there have recently been some signs of growth in the funding available for maltreatment-focused research. The recent CAPSTONE centers for child maltreatment research are a major step forward, and are likely to catalyze a new generation of mentors and junior investigators.…”

Lifetime Cost of Abusive Head Trauma at Ages 0–4, USA

“…DALYs , a standard measure of burden of disease, are computed by summing the discounted present value of life years lost by those who die prematurely plus years lived with disability by survivors (i.e., the portion of quality of life lost during those years) (Bourgeois et al 2014; Murray et al 2013). We applied published DALY estimates for AHT, as measured by the Health Utilities Index—Mark 2 (Drummond et al 2007), based on a survey of AHT caregivers and pediatricians familiar with AHT ( n = 170) (Miller et al 2014).…”

Consideraciones geográficas en la interpretación de los resultados de revisiones sistemáticas y meta-análisis: fluidos en sepsis pediátrica

“…Pero en estas mismas limitaciones radican muchos de los problemas responsables de la alta tasa de mortalidad infantil en estas áreas geográficas. Hay que considerar también que la realización de investigaciones y ensayos clínicos tiene una correlación moderada con la carga de enfermedad, especialmente en regiones con mayor pobreza 9 .…”